INTRODUCTION
Delirium is one of the most difficult syndromes to diagnose and treat in terminal cancer patients, yet it substantially impairs the quality of life for both the patient and their family near the end of life (1) . Delirium is defined as an acute confusional state which results from diffuse organic brain dysfunction (2) . According to previous surveys, the prevalence of delirium in cancer patients is from 11 to 35% (3 -6) . In terminal cancer patients, the prevalence of delirium may be as high as 85% (7) . Delirium, during hospitalization in a palliative care unit, has been found to vary between 28 and 88% (8, 9) . The exact prevalence of delirium in terminal cancer patients is unknown (10) , but frequent, close assessment results in better detection (11) . With appropriate treatment, delirium may be reversed in almost 50% of cases (11, 12) . In some terminal cancer patients, delirium can be ameliorated by identifying and managing underlying causes and providing concurrent symptomatic treatment such as pharmacotherapy (13) . However, some causes of delirium in terminal cancer patients are irreversible. Therefore, it is important to detect delirium in clinical practice to ascertain that the underlying causes are treatable or not.
Although delirium is a common psychiatric disorder in terminal cancer patients, it is not easy to diagnose by doctors and nurses in oncology and hospice units (14) . In previous studies, there were few reports on the detection rate of delirium (15 -17) . Some instruments were specifically designed for screening delirium, such as the Confusion Assessment Method, Delirium Symptom Interview, Memorial Delirium Assessment Scale and Delirium Rating Scale (DRS) (18 -21) . However, using a screening instrument to identify delirium is not common practice. In addition, many medical units do not have access to a psychiatric service. Therefore, it is even more important for doctors and nurses to be able to detect and manage delirium. The management of delirium includes the correction of underlying problems and the prescription of suitable medication (2, 5, 13, 22) . For terminal cancer patients, it is difficult to improve the underlying problems, but it is possible to decrease symptoms and signs by drug therapy, thereby improving quality of life (1, 9) . The three purposes of this prospective survey were (i) to determine the prevalence of delirium in terminal cancer inpatients; (ii) to assess the detection of delirium by clinical staff in a hospice unit and (iii) to document the pharmacotherapy for delirium.
PATIENTS AND METHODS
The survey was conducted from August 2006 to January 2007, in Mackay Hospice and Palliative Care Center, a 63 bed unit within the 2060 bed Mackay Memorial Hospital. Mackay Hospice and Palliative Care Center is the largest acute palliative care unit and the main teaching unit to offer the training for palliative care in Taiwan. The survey was approved by the Mackay Memorial Hospital Committee of Human Testing and passed the inspection of the Institutional Review Board to allow clinical research for the project. All hospitalized terminal cancer patients or their caregivers got the informed consents and were invited to participate by a research assistant who was an experienced nurse counsellor. The research assistant read the informed consent and explained the process and purpose of the survey to inpatients or caregivers. Consenting patients were entered into the study. Patients with brain metastasis were not excluded but had been recorded.
The screening instrument was the DRS-Chinese Version (DRS-C) (23) , which was translated from the DRS (21) . The DRS, developed by Trzepacz, is a useful tool in both clinical practice and research. It is has good validity, reliability, sensitivity and specificity. The DRS consists of 10 items, with a maximum score of 32. The previously validated cut-off point for probable cases of delirium is a score of 10 (sensitivity ¼ 95%, specificity ¼ 61%) in cancer patients (24) . It was previously translated into Chinese and has been used by several investigators in Taiwan (23) .
The research assistant screened all the participants with the DRS-C every two days. Before the study, the research assistant with the license of nursing had been trained how to identify delirium and how to complete the DRS-C for six months. The research assistant screened not only at admission but also during the hospitalization. When the score of DRS-C was 10 points or more, the psychiatrists performed a clinical assessment to confirm the diagnosis of delirium and determine its subtype. The psychiatrist visited the patient within 24 hours of being informed by the research assistant. The diagnostic criteria of delirium were based on the DSM-IV (25) . The hyperactive subtype of delirium was applied to patients conforming to the DSM-IV criteria of delirium with moderate or severe psychomotor hyperactivity within the first 48 hours of delirium. Patients conforming to the DSM-IV criteria of delirium with moderate or severe psychomotor hypoactivity during the first 48 hours were diagnosed as having hypoactive delirium. Patients with delirium who presented with both psychomotor hyperactivity and hypoactivity during the period were allocated to the mixed subtype (9, 28) .
To assess the detection rate of delirium, the research assistant prepared the name lists of all participants every week and asked all the treating staff to evaluate whether their patients had delirium in the past one week. In the two hospice wards, there were the team meetings for grand run every week; one was on Monday, the other was on Wednesday. Members who might join the team meetings in the two palliative care teams included three attending physicians, four residents, 54 nurses, three social workers, two senior volunteers and a pastor. The research assistant joined the meetings and promoted all staff to evaluate all inpatients on the lists of the participants for the detection of delirium. Any treatment of delirium, particularly prescription of antipsychotics, by the medical staff was recorded by the research assistant. The final status of the participants were also recorded, including death during hospitalization, discharge from hospital and transfer to home care or other hospitals.
Statistical analyses were performed using the Statistical Package for the Social Science SPSS, version 14.0, and Statistical Analysis System SAS, version 8.2 (SAS institute). Tests were two-tailed with a significance level of 0.05. In order to determine the prevalence of delirium in terminal cancer inpatients, descriptive statistics and multivariate analysis for identifying the factors related to prevalence and those related to death were used. In addition, there may be less awareness of the hypoactive subtype. Some publications have suggested that early detection of delirium in cancer patients could be promoted by greater awareness by medical staff, and improved knowledge of its delineating characteristics (30, 31) .
Distributions of continuous variables were tested for normality using the Shapiro -Wilks test. Variables with non-normal distributions were analysed using the Kruskal -Wallis H-test. Categorical variables were described using frequency distributions, x 2 -test or Fisher's exact test. The mean and median survival time of the subjects to death from the onset of delirium was analysed by using Kaplan -Meier survival analysis using the log-rank test and the Cox proportional hazard model, respectively.
RESULTS

THE CHARACTERISTICS OF TERMINAL CANCER INPATIENTS
Of a total of 457 terminal cancer patients during the survey period, 228 (49.9%) agreed to participate in the study. The remaining 229 patients included 42 (18.3%) who refused enrolment to be surveyed, 69 (30.1%) who died within 24 hours of hospitalization, 118 (51.5%) who were too ill to sign the informed consent, and others where no family or legal caregivers could be notified to sign the informed consent. The characteristics of participants are shown in Table 1 .
TERMINAL CANCER PATIENTS WITH DELIRIUM
Among 228 terminal cancer patients, the prevalence of delirium was 46.9% (n ¼ 107). There were 109 inpatients whose scores of DRS were 10 points or greater, but 2 of them were excluded by psychiatrists after the clinical assessment. As shown in Table 1 Fig. 1 , Kaplan -Meier survival analysis using the log-rank test). The mortality rate of the hyperactive and hypoactive subtypes combined was over 82%. By using the Cox proportional hazard model, as shown in Table 3 Table 5 . Haloperidol was the most commonly prescribed drug. Some atypical anti-psychotics were also prescribed, such as quetiapine and olanzapine. Pharmacotherapy correlated strongly with detection rate (x 2 ¼ 18.547, P , 0.0001, x 2 -Test).
DISCUSSION
The results of this prospective survey found a high prevalence and a low rate of detection and management of delirium in terminal cancer inpatients. The low detection and treatment rate indicates deficiencies in the quality of care by palliative care teams. This may be due to inadequate knowledge and skill in palliative care medical professionals. These are common barriers to the quality of care (26). The prevalence of delirium in our samples was 46.9%, which is comparable to other studies, which report a range from 28 to 88% (8, 9) . The proportion with hypoactive delirium, almost 70%, was also similar to other surveys. In the UK, 29.4% of 109 inpatients in a hospice ward had delirium, and 78% of these had the hypoactive subtype (27) . In contrast to the other studies, in Japan, 17 % of 1721 cancer patients with psychiatric referrals had delirium, and more than 70% were of the hyperactive subtype (5) .
Approximately half the patients in this study suffered from delirium, but more than half of these were missed by palliative care staff. Detection rates of delirium by either doctors (30%) or nurses (29%) were low. Only one patient with delirium was found by a social worker. However, the detection rate varied markedly by subtype. The detection of hyperactive and mixed delirium was nearly 100%. This was not related to the severity of delirium because the mean score of the DRS-C was similar for all three subtypes. It is more likely to be because of the obvious symptoms and signs, for example, agitation, aggressiveness and hallucination. By contrast, patients with hypoactive delirium were often sleepy, drowsy and withdrawn, so hypoactive delirium was more difficult to detect (9, 29) . In addition, there may be less awareness of the hypoactive subtype. Some publications have suggested that early detection of delirium in cancer patients could promote greater awareness in medical staff, and improve knowledge of its delineating characteristics (30, 31) . Some medical staff might misdiagnose the symptoms and signs of hypoactive delirium as another condition, such as anorexia-cachexia syndrome, because they do not fully understand the diagnostic criteria (32, 33, 34) . Not only in the palliative care team but also in the intensive care unit, hypoactive delirium is frequently missed (17, 34) .
The higher mortality of patients with delirium is another important finding of this survey as the previous studies. In cancer care, delirium is associated with a high incidence of mortality, and the incidence is even higher in terminal cancer patients (35, 36) . The disturbing symptoms of delirium also cause stress and burnout amongst caregivers (37) . Palliative care professionals should offer high quality care to both patients and caregivers, whether the delirium is reversible or not. This is especially urgent for the hypoactive subtype, in which the mean survival time is only 7.87 + 1.13 days. Therefore, detection of delirium gives an opportunity for staff and families to prepare for death, and perhaps allows better quality of life when the delirium is treated (38, 39) .
In our survey, the detection rate of delirium (44.9%, 95% CI: 35.5 -54.3%) was almost identical to the treatment rate (42.1%, 95% CI: 32.7 -51.5%) (x 2 ¼ 18.547, P , 0.0001, x 2 Test). Nearly all the patients with hyperactive delirium were treated with medications by their palliative care team. The medications used for delirium were either anti-psychotics or sedatives. Both drug types are appropriate treatment for terminal cancer patients. In the survey, there were three antipsychotics used for delirium: haloperidol (n ¼ 23), quetiapine (n ¼ 2) and olanzapine (n ¼ 1). Haloperidol is well recognized for managing the symptoms of hyperactive delirium (40) . However, it is associated with extrapyramidal syndrome and anti-cholinergic side effects (41) . In the past decade, atypical anti-psychotics, such as risperidone, olanzapine and quetiapine, have been used for delirium in palliative care (41, 43) . Quetiapine and olanzapine are better tolerated than haloperidol in severely ill patients (44 -46) . Atypical anti-psychotics might be the most appropriate medication for delirium in terminal cancer patients. Sedation with an opioid or benzodiazepine is the other management of delirium in terminal cancer patients (47 -49) . In our survey, nearly half the prescriptions for delirium were part of palliative sedation therapy (47, 48) . In palliative care units in Japan, palliative sedation therapy was performed in accordance with the ethical principles of double effect, proportionality and autonomy (47) . The practice in Taiwan is very similar. Our study has several limitations. First, the response rate was approximately 50%. The survey was a prospective study inviting all hospitalized terminal cancer patients to participate, so it was not easy to have a high response rate. In Asia, terminal cancer inpatients and their families usually wish for a peaceful final phase of life (50) . Many families declined to participate because they thought the study would impair such a peaceful passing. Second, the fact that the survey was of short duration, and confined to a single teaching hospital may mean that the results cannot be generalized. (51) . Third, there were insufficient numbers of patients to enable a breakdown of the prevalence of delirium by cancer type. This same difficulty has been noted in other studies (8, 11, 52) . Fourth, the sample size was insufficient to compare the efficacy of the different medications, although our results were consistent with the literature (40 -49) . Fifth, before psychiatric diagnostic interview, screening was conducted by the research assistant, so we could not understand the incidence of the other psychiatric disorders among terminal cancer patients. Sixth, we could not explain the result about patients below 59 years old had a higher risk of mortality than patients over 80 years old. There were not enough data for analysis. The further survey about the phenomenon should be considered.
Despite these limitations, we have two recommendations for improving the detection of delirium and increasing the prescription of atypical anti-psychotics for terminal cancer inpatients with hypoactive delirium or another subtype delirium. The first suggestion is increased education in the field of psycho-oncology for all medical professionals who care for cancer patients (53, 54) . Specifically, staff need to be taught how to identify and treat delirium, and how to care for and support patients and caregivers (55) . How to prescribe haloperidol or any other anti-psychotics for delirium and whether to prescribe or not among different subtype of delirium should be attached importance and be discussed as an ethical issue in further studies. The second suggestion is to reinforce the collaboration between palliative care teams and psychiatrists. Staffing levels in palliative care teams is usually sufficient to take care of patients and caregivers, but they may lack skills in the psychiatric domain. This deficiency can be rectified by close collaboration between a psychiatric service and a palliative care team, as we have developed in the two hospice wards in Mackay Memorial Hospital (56) . This concept of a 'consultation-liaison psychiatry' service to the oncology units and the palliative care teams is underdeveloped in Taiwan.
In conclusion, delirium is a common and important problem in terminal cancer inpatients, causing increased morbidity and mortality. This survey found that it was significantly underdiagnosed and undertreated. Better detection and treatment should be a priority. The pharmacotherapy of delirium with different kinds of anti-psychotics should be broadly recognized by staff in palliative care unite. Staff education and the creation of a psycho-oncology liaison service are recommended.
